Last reviewed · How we verify
1% tropicamide and 2.5% phenylephrine
At a glance
| Generic name | 1% tropicamide and 2.5% phenylephrine |
|---|---|
| Sponsor | Khon Kaen University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pharmacodynamics of a Fixed Dose Combination of 0.34% Tropicamide and 2.5% Phenylephrine Hydrochloride, Eye Drop, Solution (PHASE1, PHASE2)
- Contribution of the Kinematic Theory in the Early Differential Diagnosis of the Parkinson's Disease
- Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients (PHASE4)
- Safety and Efficacy of Fixed Combination Phenylephrine-Tropicamide for Pupil Dilation (PHASE4)
- The Effect of Brimonidine (PHASE4)
- The Effects of Mydriatic Eye Drops in Retinopathy of Prematurity Examinations
- Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation (PHASE3)
- Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 1% tropicamide and 2.5% phenylephrine CI brief — competitive landscape report
- 1% tropicamide and 2.5% phenylephrine updates RSS · CI watch RSS
- Khon Kaen University portfolio CI